KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Bionano Genomics (BNGO) Cost of Revenue (2017 - 2025)

Historic Cost of Revenue for Bionano Genomics (BNGO) over the last 9 years, with Q3 2025 value amounting to $4.0 million.

  • Bionano Genomics' Cost of Revenue fell 7247.06% to $4.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.5 million, marking a year-over-year decrease of 5426.87%. This contributed to the annual value of $30.4 million for FY2024, which is 1448.59% up from last year.
  • Per Bionano Genomics' latest filing, its Cost of Revenue stood at $4.0 million for Q3 2025, which was down 7247.06% from $3.3 million recorded in Q2 2025.
  • Over the past 5 years, Bionano Genomics' Cost of Revenue peaked at $14.5 million during Q3 2024, and registered a low of $2.1 million during Q1 2021.
  • Moreover, its 5-year median value for Cost of Revenue was $5.2 million (2022), whereas its average is $5.5 million.
  • In the last 5 years, Bionano Genomics' Cost of Revenue surged by 30082.92% in 2021 and then tumbled by 7247.06% in 2025.
  • Quarter analysis of 5 years shows Bionano Genomics' Cost of Revenue stood at $6.1 million in 2021, then grew by 5.72% to $6.4 million in 2022, then increased by 29.22% to $8.3 million in 2023, then crashed by 42.7% to $4.7 million in 2024, then decreased by 15.78% to $4.0 million in 2025.
  • Its Cost of Revenue was $4.0 million in Q3 2025, compared to $3.3 million in Q2 2025 and $3.5 million in Q1 2025.